|
| Press Releases |
|
 |
|
| Tuesday, July 15, 2025 |
|
|
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease |
| AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB). more info >> |
|
| Monday, May 5, 2025 |
|
|
Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards |
| Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech's new Gene Therapy Center with dedicated cGMP facilities for virus-related projects. more info >> |
|
| Tuesday, March 4, 2025 |
|
|
Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program |
| Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis. more info >> |
|
| Tuesday, February 4, 2025 |
|
|
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment |
| Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth. more info >> |
|
| Tuesday, August 1, 2023 |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
| Thursday, May 25, 2023 |
|
|
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts |
| Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape. more info >> |
|
| Wednesday, May 17, 2023 |
|
|
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat |
| tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
AAC Technologies CFO Guo Dan: Accelerating Expansion into AI Blue Ocean for a New Revenue Milestone in 2026
Mar 26, 2026 14:43 HKT/SGT
|
|
|
Hitachi Rail to manufacture rolling stock for Seibu Railway"s new Fine Dining Train
Mar 26, 2026 15:13 JST
|
|
|
Nissin Foods Announces 2025 Annual Results
Mar 26, 2026 12:21 HKT/SGT
|
|
|
CALB (03931.HK) Achieves Mass Production Roll-off of Pioneering Aviation Battery System, Powered by Advanced R46 Cylindrical Batteries
Mar 26, 2026 10:56 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 26, 2026 10:49 HKT/SGT
|
|
|
Royal Healthcare in Singapore provides NEC's "FonesVisuas Test" for Disease Risk Prediction
Mar 26, 2026 11:21 JST
|
|
|
MHI-AP Awarded Boiler Retrofit Contract for Waste-to-Energy Facility in Singapore
Mar 26, 2026 11:07 JST
|
|
|
TransNusa Becomes First Indonesian Airline to Receive Additional Flight Frequencies from World-Renowned Changi Airport in 2026
Mar 26, 2026 09:30 HKT/SGT
|
|
|
Formerra Announces Transportation Surcharge to Address Ongoing Freight and Logistics Market Pressures
Mar 26, 2026 04:00 HKT/SGT
|
|
|
Aleen Inc. Introduces Biomarker Data Layer in Personal Wellness Account
Mar 25, 2026 23:28 HKT/SGT
|
|
|
Hengrui Pharma Announces Strong 2025 Annual Results
Mar 25, 2026 23:15 HKT/SGT
|
|
|
Everbright Grand China Assets Recorded Revenue of RMB49.9 Million in 2025
Mar 25, 2026 22:39 HKT/SGT
|
|
|
Lithium Measurement MR-Technology Provider NanoNord Expands Business with DLE Leader ElectraLith, Following Danish State Visit to Australia
Mar 25, 2026 20:30 HKT/SGT
|
|
|
Adyton Reports 6.60g/t Au, 2.44% Cu and 39.8g/t Ag Within 164m @ 0.82g/t AuEq Including 53m at 1.60g/t AuEq Within 164m at 0.82g/t AuEq from the Northeastern Extension Target, Feni Island
Mar 25, 2026 19:29 HKT/SGT
|
|
|
Emperor Watch & Jewellery Limited Announces 2025 Annual Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
